Flexus Biosciences
Acquired by Bristol Myers Squibb
Is this your company?
Find the right fit for you - faster
Get tailored insights about working at Flexus Biosciences in one quick step.
Flexus Biosciences Snapshot
The acquisition will give Bristol-Myers Squibb full rights to F001287, Flexus’ lead preclinical small molecule IDO1-inhibitor targeted for IND filing in the second half of 2015. In addition, Bristol-Myers Squibb will acquire Flexus’ IDO/TDO discovery program which includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries. FLX Bio, a spinout entity, was then established by the current shareholders of Flexus which retained, from and after the closing, all non-IDO/TDO assets of Flexus including those related to Flexus’ Phase 1 FLT3 and CDK4/6 inhibitor, its earlier stage small-molecule Treg cancer immunotherapy programs, and its current personnel and facilities.
